浏览全部资源
扫码关注微信
沙库巴曲缬沙坦在射血分数下降心衰患者中的应用分析
Real-world application of sacubitril/valsartan in patients suffering from heart failure with reduced ejection fraction
- 第三军医大学学报 2020年42卷第21期 页码：2122-2127
- 作者机构：
400037 重庆，陆军军医大学(第三军医大学)第二附属医院心血管内科，全军心血管病研究所
- 作者简介：
[王江，E-mail: 1530579054@qq.com WANG Jiang, E-mail: 1530579054@qq.com
- 基金信息：陆军军医大学第二附属医院临床科研课题(2015YLC11)
DOI：10.16016/j.1000-5404.202006167
中图分类号： R541.6;R969.4;R972收稿：2020-06-11，
修回：2020-08-29，
纸质出版：2020-11-15
- 稿件说明：
移动端阅览
罗晓宇, 陈运龙, 陈沿辛, 等. 沙库巴曲缬沙坦在射血分数下降心衰患者中的应用分析[J]. 第三军医大学学报, 2020,42(21):2122-2127.
Xiaoyu LUO, Yunlong CHEN, Yanxin CHEN, et al. Real-world application of sacubitril/valsartan in patients suffering from heart failure with reduced ejection fraction[J]. Journal of Third Military Medical University, 2020, 42(21): 2122-2127.
罗晓宇, 陈运龙, 陈沿辛, 等. 沙库巴曲缬沙坦在射血分数下降心衰患者中的应用分析[J]. 第三军医大学学报, 2020,42(21):2122-2127. DOI： 10.16016/j.1000-5404.202006167.
Xiaoyu LUO, Yunlong CHEN, Yanxin CHEN, et al. Real-world application of sacubitril/valsartan in patients suffering from heart failure with reduced ejection fraction[J]. Journal of Third Military Medical University, 2020, 42(21): 2122-2127. DOI： 10.16016/j.1000-5404.202006167.
摘要
目的
2
探讨射血分数下降心衰患者(heart failure with reduced ejection fraction，HFrEF)在真实临床实践中使用沙库巴曲缬沙坦(sacubitril/valsartan，ARNI)的治疗效果、对心脏结构和功能的影响以及治疗的剂量。
方法
2
收集本院2017年9月至2020年2月启用ARNI治疗HFrEF患者共118例，中位随访8(6~12)个月，通过对比ARNI治疗前后的临床资料，回顾性分析HFrEF患者的纽约心功能分级(New York Heart Association
NYHA)改善、心肌结构改变及心力衰竭再入院率情况，并观察ARNI治疗HFrEF患者的药物副作用及用药现状。
结果
2
118例HFrEF患者经ARNI治疗后心功能分级改善≥1级占83.1%，治疗总有效率为83.1%，左室射血分数(left ventricular ejection fraction，LVEF)明显升高，左房前后径(left atrial diameter，LAD)、左室舒张末内径(left ventricular end-diastolic diameter，LVEDD)、右房横径(right atrium left-right dimension，RA)、右室横径(right ventricle left-right dimension，RV)均明显减小，差异均有统计学意义(
P
<
0.001)。ARNI目标维持剂量(200 mg，bid)达标率为3.4%，心力衰竭再入院率为24.6%，药物的不良反应包括症状性低血压(14例，11.9%)和皮肤瘙痒(2例，1.7%)。
结论
2
尽管ARNI在临床应用中存在维持剂量偏低的问题，但仍可显著改善HFrEF患者的心脏结构和功能。症状性低血压是ARNI的常见不良反应以及造成ARNI目标维持剂量达标率低的主要原因。
Abstract
Objective
2
To observe and analyze the efficacy
the effect on cardiac structure and function and the dosage of sacubitril/valsartan (ARNI) in real clinical practice in patients with heart failure with reduced ejection fraction (HFrEF).
Methods
2
A total of 118 HFrEF patients treated with ARNI in our hospital from September 2017 to February 2020 were recruited in this study. Their clinical data before and after treatment were collected. After all of them were followed up for a median time of 8 (6 to 12) months
the changes of New York Heart Association (NYHA) classification of cardiac function and myocardial structure
and the readmission due to heart failure were analyzed retrospectively. The side effects and current situation of drug use were also observed among these patients.
Results
2
After ARNI treatment
the improvement of NYHA grade ≥1 accounted for 83.1% of the HFrEF patients
and the total effective rate of treatment was 83.1%. They obtained significantly increased left ventricular ejection fraction (LVEF) (
P
<
0.001)
and obviously decreased left atrial anterior and posterior diameter (LAD)
left ventricular end-diastolic diameter (LVEDD)
right atrial left-right diameter (RA) and right ventricular left-right dimension (RV) (
P
<
0.001). During the follow-up period
the target dose (200 mg
bid) rate of ARNI was 3.4% and the readmission rate of heart failure was 24.6%. Adverse reactions of drugs included symptomatic hypotension (14 cases
11.9%) and skin pruritus (2 cases
1.7%).
Conclusion
2
Although ARNI has the problem of being maintained at low dose in clinical application
it can still significantly improve the cardiac structure and function of HFrEF patients. Symptomatic hypotension is the common adverse reaction in the use of ARNI and the main reason for the low rate of ARNI target maintenance dose.
关键词
Keywords
references
中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会, 等.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志, 2018, 2(4): 196-225. DOI:10.3760/cma.j.issn.2096-3076.2018.12.002.
Heart Failure Group of Branch of Cardiology of Chinese Medical Association; Chinese Heart Failure Society of Chinese Medical Doctor Association; Editorial Board of Chinese Journal of Cardiology, et al . Chinese guidelines for diagnosis and treatment of heart failure 2018[J ] . Chin J Cardiol, 2018, 2(4): 196-225. DOI:10.3760/cma.j.issn.2096-3076.2018.12.002.
SAYAGO SILVA I, GARCÍA-LÓPEZ, SEGOVIACUBERO J. Epidemiology of heart failure in Spain over the last 20 years[J]. Rev Esp Cardiol (Engl Ed), 2013, 66(8): 649-656. DOI: 10.1016/j.rec.2013.03.012.
SAVARESE G, LUND L H. Global public health burden of heart failure[J]. Card Fail Rev, 2017, 3(1): 7-11. DOI:10.15420/cfr.2016:25:2.
戴雯莉, 吴翔宇, 王苏, 等.沙库巴曲缬沙坦治疗慢性充血性心力衰竭患者的临床研究[J].中国医药, 2019, 14(9): 1297-1301. DOI: 10.3760/j.issn.1673-4777.2019.09.005.
DAI W L, WU X Y, WANG S, et al . Clinical research on sacubitril/valsartan treating patients with chronic congestive heart failure[J ] . Chin Med, 2019, 14(9): 1297-1301.DOI: 10.3760/j.issn.1673-4777.2019.09.005.
中华医学会心血管病学分会, 中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中国实用乡村医生杂志, 2015, 22(4): 3-5.DOI: 10.3969/j.issn.1672-7185.2015.04.002.
Branch of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiovascular Disease. China Heart Failure Diagnosis and Treatment Guidelines 2014[J]. Chin Pract J Rural Doctor, 2015, 22(4): 3-5.DOI: 10.3969/j.issn.1672-7185.2015.04.002.
MCMURRAY J J, PACKER M, DESAI A S, et al . Angiotensin-neprilysin inhibition versus enalapril in heart failure[J ] . N Engl J Med, 2014, 371(11): 993-1004. DOI:10.1056/NEJMoa1409077.
苏斌杰, 俞飞虎, 程劲松, 等.沙库巴曲缬沙坦钠治疗扩张型心肌病临床疗效观察[J].心脑血管病防治, 2019, 19(6): 570-572. DOI: 10.3969/j.issn.1009_816x.2019.06.028.
SU B J, YU F H, CHENG J S, et al . Clinical observation on the therapeutic effect of ARNI sodium in the treatment of dilated cardiomyopathy[J ] . Prevent Treatf Cardio-Cerebral-Vascular Dis, 2019, 19(6): 570-572.DOI: 10.3969/j.issn.1009_816x.2019.06.028.
MARTENS P, BELIEN H, DUPONT M, et al . The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction[J ] . Cardiovasc Ther, 2018, 36(4): e12435. DOI:10.1111/1755-5922.12435.
FOX M E, BUCHER E S, JOHNSON J A, et al . Medullary norepinephrine projections release norepinephrine into the contralateral bed nucleus of the stria terminalis[J ] . ACS Chem Neurosci, 2016, 7(12): 1681-1689. DOI: 10.1021/Acschemneuro.6b00210.
王天娇, 周琳, 刘一航, 等.评估心力衰竭预后相关指标的研究进展[J].中国循证心血管医学杂志, 2017, 9(3): 374-376. DOI: 10.3969/j.issn.1674-4055.2017.03.35.
WANG T J, ZHOU L, LIU Y H, et al . Research progress of prognostic indicators for heart failure[J ] . Chin J Evid-Based Cardiol Med, 2017, 9(3): 374-376. DOI: 10.3969/j.issn.1674-4055.2017.03.35.
MANGIAFICO S, COSTELLO-BOERRIGTER L C, ANDERSEN I A, et al . Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics[J ] . Eur Heart J, 2013, 34(12): 886-893.DOI: 10.1093/eurheartj/ehs262.
KOBALAVA Z, KOTOVSKAYA Y, AVERKOV O, et al . Pharmacodynamic and pharmacokinetic profiles of sacubitril/valsartan (LCZ696) in patients with heart failure and reduced ejection fraction[J ] . Cardiovasc Ther, 2016, 34(4): 191-198. DOI:10.1111/1755-5922.12183.
MARTENS P, BELIËN H, DUPONT M, et al . Insights into implementation of sacubitril/valsartan into clinical practice[J ] . ESC Heart Fail, 2018, 5(3): 275-283. DOI:10.1002/ehf2.12258.
WACHTER R, VIRIATO D, KLEBS S, et al . Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany[J ] . Postgrad Med, 2018, 130(3): 308-316. DOI:10.1080/00325481.2018.1442090.
SENNI M, MCMURRAY J J, WACHTER R, et al . Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens[J ] . Eur J Heart Fail, 2016, 18(9): 1193-1202. DOI:10.1002/ejhf.548.
BÖHM M, YOUNG R, JHUND P S, et al . Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF[J ] . Eur Heart J, 2017, 38(15): 1132-1143. DOI:10.1093/eurheartj/ehw570.
AMBROSY A P, VADUGANATHAN M, MENTZ R J, et al . Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the efficacy of vasopressin antagonism in heart failure: outcome study with tolvaptan (EVEREST) trial[J ] . Am Heart J, 2013, 165(2): 216-225. DOI: 10.1016/j.ahj.2012.11.004.
VARDENY O, CLAGGETT B, PACKER M, et al . Efficacy of sacubitril/valsartan vs . enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial[J ] . Eur J Heart Fail, 2016, 18(10): 1228-1234. DOI:10.1002/ejhf.580..
VOLPE M, RUBATTU S, BATTISTONI A. ARNI: A novel approach to counteract cardiovascular diseases[J]. Int J Mol Sci, 2019, 20(9): 2092. DOI:10.3390/ijms20092092.
SOLOMON S D, RIZKALA A R, LEFKOWITZ M P, et al . Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial[J ] . Circ Heart Fail, 2018, 11(7): e4962.DOI:10.1161/CIRCHEARTFAILURE.118.004962.
0
浏览量
0
下载量
0
CSCD
- 网络PDF下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
